Clinical Trial Update: Imatinib Mesylate in Treating Patients With Salivary Gland Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of Imatinib Mesylate for salivary gland cancer (a form of head and neck cancer) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Salivary Gland Cancer

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED